Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study
- PMID: 35293103
- DOI: 10.1111/hiv.13250
Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study
Abstract
Introduction: We aimed to investigate the relationship between low-level viremia (LLV) and virological failure (VF), death, and non-AIDS events (NAEs).
Methods: A prospective cohort study of people living with HIV (PLHIV) on antiretroviral therapy (ART) was conducted from 2011-2018 at an HIV clinic in Shenyang, China. The incidence of VF and the mortality and NAEs due to LLV were assessed. Cox proportional hazards regression was performed to investigate risk factors for VF, mortality, and NAEs.
Results: In total, 1288 patients, contributing 3915 person-years of follow-up (median follow-up, 2.5 years [interquartile range: 2-4 years]), were enrolled. Thirty-one patients (2.4%) experienced VF, 5 (0.4%) died, and 38 (3.0%) experienced NAEs. The risk of VF was significantly increased among patients with a viral load (VL) of 200-499 copies/mL (adjusted hazard ratio [aHR]: 14.92, 95% confidence interval [CI]: 5.92-37.60) or 500-999 copies/mL (aHR: 13.68, 95% CI: 3.61-51.87), but not among patients with a VL of 50-199 copies/mL (aHR: 3.10, 95% CI: 0.86-11.09). The risk of NAEs was significantly increased among patients with LLV (aHR: 7.33, 95% CI: 3.73-14.42). Compared to no LLV, a VL of 50-199 copies/mL (aHR: 4.11, 95% CI: 1.73-9.74), 200-499 copies/mL (aHR: 18.31, 95% CI: 6.66-50.33), and 500-999 copies/mL (aHR: 21.34, 95% CI: 5.69-80.01) showed higher risk of NAEs.
Conclusion: Low-level viremia was associated with VF and NAEs. Patients with LLV, especially those with a VL ≥200 copies/mL, may need more frequent VL testing and NAE screening.
Keywords: China; low-level viremia; non-AIDS events; people living with HIV; virological failure.
© 2022 British HIV Association.
Similar articles
-
Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.Viruses. 2024 May 1;16(5):720. doi: 10.3390/v16050720. Viruses. 2024. PMID: 38793602 Free PMC article.
-
Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).Antivir Ther. 2015;20(6):655-60. doi: 10.3851/IMP2949. Epub 2015 Mar 4. Antivir Ther. 2015. PMID: 25735799
-
All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.Clin Infect Dis. 2021 Jun 15;72(12):2079-2086. doi: 10.1093/cid/ciaa413. Clin Infect Dis. 2021. PMID: 32271361 Free PMC article.
-
Clinical significance and management of low-level HIV viremia in the era of integrase strand transfer inhibitors.HIV Med. 2024 Mar;25(3):361-369. doi: 10.1111/hiv.13585. Epub 2023 Nov 22. HIV Med. 2024. PMID: 37990782 Review.
-
Impact of low-level viremia on HIV non-viral load suppression in low and middle-income countries.Ann Med Surg (Lond). 2025 Apr 10;87(6):3777-3785. doi: 10.1097/MS9.0000000000003272. eCollection 2025 Jun. Ann Med Surg (Lond). 2025. PMID: 40486603 Free PMC article. Review.
Cited by
-
Laboratory Report of HIV-1 Low-Level Viremia.Open Forum Infect Dis. 2024 Jan 11;11(2):ofad667. doi: 10.1093/ofid/ofad667. eCollection 2024 Feb. Open Forum Infect Dis. 2024. PMID: 38352153 Free PMC article. No abstract available.
-
Low Level Viremia Is Associated With Serious non-AIDS Events in People With HIV.Open Forum Infect Dis. 2024 Mar 30;11(4):ofae147. doi: 10.1093/ofid/ofae147. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38628953 Free PMC article.
-
The prevalence of low-level viraemia and its association with virological failure in people living with HIV: a systematic review and meta-analysis.Emerg Microbes Infect. 2025 Dec;14(1):2447613. doi: 10.1080/22221751.2024.2447613. Epub 2025 Jan 8. Emerg Microbes Infect. 2025. PMID: 39727007 Free PMC article.
-
Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.J Virus Erad. 2023 Mar 4;9(1):100320. doi: 10.1016/j.jve.2023.100320. eCollection 2023 Mar. J Virus Erad. 2023. PMID: 37008574 Free PMC article. Review.
-
A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era.Curr HIV/AIDS Rep. 2025 Jun 26;22(1):39. doi: 10.1007/s11904-025-00743-2. Curr HIV/AIDS Rep. 2025. PMID: 40569488 Review.
References
REFERENCES
-
- Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2:e35-e46.
-
- Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:405-406.
-
- Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-248.
-
- Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One. 2016;11:e0147484.
-
- U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad... Accessed 15 November, 2021
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical